OBJECTIVE: We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation will decrease acute lung injury following hemorrhagic shock, by inhibiting the release of epithelial derived proinflammatory mediators. DESIGN: Animal study. SETTING: Animal-care facility procedure room in a medical center. SUBJECTS: Adult male Sprague-Dawley rats. INTERVENTIONS: Rats underwent hemorrhagic shock followed by 2 hrs of resuscitation and 1 hr of observation. In the study group, nebulized hypertonic saline was delivered at the end of the shock period and after 1 hr and 2 hrs of resuscitation. MEASUREMENTS AND MAIN RESULTS: Shock provoked acute lung injury, which was attenuated with inhaled hypertonic saline (1.56 ± 0.2 mg protein/mL vs. 0.95 ± 0.3 mg protein/mL bronchoalveolar lavage fluid, shock vs. shock + hypertonic saline, p < .01). Nebulized hypertonic saline reduced inflammation (cytokine-induced neutrophil chemoattractant-1 accumulation in bronchoalveolar lavage fluid 5999 ± 1267 pg/mL vs. 3342 ± 859 pg/mL, shock vs. shock + hypertonic saline, p = .006). Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13 accumulation in the bronchoalveolar lavage fluid (1513 ± 337 pg/mL bronchoalveolar lavage fluid vs. 230 ± 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a matrix metalloproteinase-13 inhibitor was sufficient to attenuate postshock acute lung injury (1.42 ± 0.09 mg/mL vs. 0.77 ± 0.23 mg/mL bronchoalveolar lavage protein, shock vs. shock + matrix metalloproteinase-13 inhibitor CL-82198, p = .002). CONCLUSION: Inhaled hypertonic saline attenuates postshock acute lung injury by exerting an anti-inflammatory effect on the pulmonary epithelium, suggesting a new clinical strategy to treat acute lung injury/acute respiratory distress syndrome.
OBJECTIVE: We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation will decrease acute lung injury following hemorrhagic shock, by inhibiting the release of epithelial derived proinflammatory mediators. DESIGN: Animal study. SETTING: Animal-care facility procedure room in a medical center. SUBJECTS: Adult male Sprague-Dawley rats. INTERVENTIONS:Rats underwent hemorrhagic shock followed by 2 hrs of resuscitation and 1 hr of observation. In the study group, nebulized hypertonic saline was delivered at the end of the shock period and after 1 hr and 2 hrs of resuscitation. MEASUREMENTS AND MAIN RESULTS: Shock provoked acute lung injury, which was attenuated with inhaled hypertonic saline (1.56 ± 0.2 mg protein/mL vs. 0.95 ± 0.3 mg protein/mL bronchoalveolar lavage fluid, shock vs. shock + hypertonic saline, p < .01). Nebulized hypertonic saline reduced inflammation (cytokine-induced neutrophil chemoattractant-1 accumulation in bronchoalveolar lavage fluid 5999 ± 1267 pg/mL vs. 3342 ± 859 pg/mL, shock vs. shock + hypertonic saline, p = .006). Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13 accumulation in the bronchoalveolar lavage fluid (1513 ± 337 pg/mL bronchoalveolar lavage fluid vs. 230 ± 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a matrix metalloproteinase-13 inhibitor was sufficient to attenuate postshock acute lung injury (1.42 ± 0.09 mg/mL vs. 0.77 ± 0.23 mg/mL bronchoalveolar lavage protein, shock vs. shock + matrix metalloproteinase-13 inhibitor CL-82198, p = .002). CONCLUSION: Inhaled hypertonic saline attenuates postshock acute lung injury by exerting an anti-inflammatory effect on the pulmonary epithelium, suggesting a new clinical strategy to treat acute lung injury/acute respiratory distress syndrome.
Authors: José L Pascual; Lorenzo E Ferri; Andrew J E Seely; Giuseppina Campisi; Prosanto Chaudhury; Betty Giannias; David C Evans; Tarek Razek; René P Michel; Nicolas V Christou Journal: Ann Surg Date: 2002-11 Impact factor: 12.969
Authors: Jennifer M Watters; Susan I Brundage; S Rob Todd; Nathan A Zautke; J A Stefater; J C Lam; Patrick J Muller; Darren Malinoski; Martin A Schreiber Journal: Shock Date: 2004-09 Impact factor: 3.454
Authors: Kinga A Powers; James Woo; Rachel G Khadaroo; Giuseppe Papia; Andras Kapus; Ori D Rotstein Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: José L Pascual; Kosar A Khwaja; Lorenzo E Ferri; Betty Giannias; David C Evans; Tarek Razek; René P Michel; Nicolas V Christou Journal: J Trauma Date: 2003-01
Authors: Ashley L Waldron; Patricia A Schroder; Kelly L Bourgon; Jessie K Bolduc; James L Miller; Adriana D Pellegrini; Amanda L Dubois; Magdalena Blaszkiewicz; Kristy L Townsend; Sandra Rieger Journal: J Diabetes Complications Date: 2017-12-06 Impact factor: 2.852
Authors: Antonio Artigas; Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Michael A Matthay Journal: Ann Transl Med Date: 2017-07
Authors: William D Cornwell; Cynthia Kim; Alejandra C Lastra; Chandra Dass; Sudhir Bolla; He Wang; Huaqing Zhao; Frederick V Ramsey; Nathaniel Marchetti; Thomas J Rogers; Gerard J Criner Journal: Biomarkers Date: 2018-11-19 Impact factor: 2.658
Authors: Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney Journal: World J Crit Care Med Date: 2015-08-04
Authors: Monika Dzieciatkowska; Angelo D'Alessandro; Ernest E Moore; Max Wohlauer; Anirban Banerjee; Christopher C Silliman; Kirk C Hansen Journal: Shock Date: 2014-12 Impact factor: 3.454
Authors: Angelo D'Alessandro; Monika Dzieciatkowska; Erik D Peltz; Ernest E Moore; Janeen R Jordan; Christopher C Silliman; Anirban Banerjee; Kirk C Hansen Journal: Shock Date: 2014-12 Impact factor: 3.454